AC
BBIO icon

Athanor Capital’s BridgeBio Pharma BBIO Stock Holding History

Athanor Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-20,000
Closed -$937K – 41
2021
Q3 		$937K Hold
20,000
– – 0.12% 156
2021
Q2 		$1.22M Buy
+20,000
New +$1.14M 0.04% 219

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Athanor Capital's BBIO Position: Q2 2021 in Review

Athanor Capital sold out of BridgeBio Pharma (BBIO) in Q2 2021, closing a stake of 5,131 shares — an estimated $293K sold.

Athanor Capital first reported a position in BBIO in Q3 2019 and held it in 6 quarters. The position peaked at $1.24M in Q4 2019. 200 funds tracked by Wall St. Rank hold BBIO as of Q2 2021.

  • Athanor Capital reported no remaining BridgeBio Pharma position as of Q2 2021 after selling out during the quarter.
  • Athanor Capital sold 5,131 BridgeBio Pharma shares in Q2 2021, an estimated $293K.
  • Athanor Capital first reported a position in BridgeBio Pharma in Q3 2019 and held it in 6 quarters.
  • Athanor Capital's BridgeBio Pharma position peaked at $1.24M in Q4 2019.
  • 200 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2021.

Based on Athanor Capital's 13F filing for Q2 2021, filed 16 Aug 2021.